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Background: Sialoadhesin (Sn)-expressing monocytes/macrophages have been associated with several diseases like
inflammatory and autoimmune disorders as well as viral infections, and they also appear to play a role in the
initiation of an adaptive immune response. This makes Sn-expressing cells not only attractive targets for cell-
directed therapies, but also an appealing target for vaccination. Furthermore, since Sn was shown to be an
endocytic receptor, the conjugation of effector molecules to an Sn-specific ligand should allow intracellular delivery
of these conjugates. Previously, we developed functional Sn-specific immunoconjugates that were generated via
chemical coupling. Although successful, the system requires significant optimization for each immunoconjugate to
be made. To generate a more flexible and controlled system, we developed a recombinant antibody vector
allowing the creation of genetic antibody fusion constructs. This paper reports on the characterization of the
recombinant antibody and the evaluation of its use for Sn-directed targeting.
Results: The variable domains of the porcine Sn-specific monoclonal antibody 41D3 were sequenced and cloned in
frame with a mouse IgG1 backbone. Transfection of HEK293T cells with the resulting plasmid led to the secretion of
fully assembled IgG into the culture medium. This recombinant antibody rec41D3 was shown to specifically bind to
porcine Sn with a comparable affinity as the native monoclonal antibody. In addition, rec41D3 also induced Sn
endocytosis in primary macrophages and resided for prolonged times in early/late endosomes. To allow the
generation of antibody fusion constructs, a multiple cloning site was introduced at the C-terminus of the heavy
chain. Two fusion constructs were generated, one containing a V5 peptide tag and one containing an eGFP
molecule. Both constructs were shown to be efficiently produced in HEK293T cells and easily purified using
standard protein G chromatography. In addition, both V5 and eGFP were shown to be co-internalized together
with rec41D3 into Sn-expressing primary macrophages.
Conclusions: A recombinant antibody allowing targeted delivery of peptides and proteins to Sn-expressing
macrophages was developed. Production and purification of antibody fusion constructs was possible without major
optimization and with batch to batch consistency, confirming the development of a versatile antibody vector to
evaluate Sn-directed targeting strategies in a porcine animal model.
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Sialoadhesin-expressing (Sn+) macrophages have gained
increased attention lately because of their unique distri-
bution in lymphoid organs and their redistribution upon
immune activation [1]. Situated in the spleen and other
secondary lymphoid tissues, Sn+ macrophages appear to
be strategically placed for antigen acquisition and deli-
very to lymphocytes. Junt et al. showed that in lymph
nodes, Sn+ macrophages capture viral particles (vesicular
stomatitis virus) within minutes after subcutaneous in-
jection, transport them across the subcapsular sinus
floor and present them to migrating B cells in the under-
lying follicles [2]. Moreover, also particulate antigen and
immune complexes have been shown to be captured and
displayed by Sn+ macrophages [3-5]. Besides, Sn+ macro-
phages present lipid antigens in a CD1d dependent man-
ner to iNKT cells, leading to iNKT cell activation and
population expansion [6]. Also, Sn+ macrophages have
been implicated in the activation of CD8+ T cells by
either directly presenting antigen to CD8+ T cells [7] or
by transferring the antigen to CD8+ dendritic cells in
the spleen [8]. Ultimately, several independent research
groups showed an enhanced cellular and/or humoral
immune response upon Sn-targeted antigen delivery
[9-13]. Together, this suggests that Sn+ macrophages
may act as specialized antigen presenting cells involved
in the antigen transport chain and contribute to the
growing interest in Sn+ macrophages for vaccination
strategies, as recently reviewed by Martinez-Pomares
and Gordon [1].
Sn (CD169, Siglec-1) is also present on inflammatory
macrophages and activated monocytes [14,15]. In af-
fected tissue samples of rheumatoid arthritis patients
for instance, high expression of Sn was found on inflam-
matory macrophages [14]. In addition, abundant Sn ex-
pression on inflammatory monocytes/macrophages was
shown to correlate with disease severity in pathological
conditions like multiple sclerosis, atherosclerosis and
breast cancer [16-18]. These observations promote the
idea of an Sn-directed cell therapy aimed at elimination
or immunomodulation of these cells. Recently, targeted
delivery of an anti-TNF-α oligonucleotide to Sn+ macro-
phages resulted in the relief of lupus-like symptoms in
mice [19], further showing the potential of Sn+ macro-
phages as a target for immunomodulation. Sn seems
thus a promising target for cell-directed therapy, a strategy
that is further encouraged by the restricted expression
pattern of Sn limiting unwanted side effects. Furthermore,
since Sn was suggested to be an endocytic receptor
[10,13], the conjugation of antigens, toxins or drugs to an
Sn-specific antibody should allow intracellular delivery of
these conjugates.
So far, three systems have been used to selectively tar-
get Sn+ macrophages, namely antibodies, glycan-coatedliposomes and cationic agarose hydrogels [9-13,19,20].
While the latter was unintentionally identified as an Sn-
targeting system [19], the glycans on the glycan-coated
liposomes were specifically designed to be ligands with
a high specificity and affinity for Sn [20]. Previously, our
research group has made use of an Sn-specific monoclo-
nal antibody (mAb) to generate functional Sn-specific
immunoconjugates via chemical coupling [10]. Although
successful, this system implies, just like the two other de-
scribed Sn-targeting systems, that the cargo to be targeted
is independently produced and purified, which translates
into significant optimization for each separate conjugate.
Also, chemical coupling to antibodies depends on the
presence and distribution of reactive groups, e.g. primary
amines on lysine residues, that can be located in or near
the antigen-binding region. Upon coupling, this might
result in partial or complete loss of the antibody’s capacity
to bind to the target antigen. In addition, there is limited
stoichiometric control because of the large number of
reactive groups present in an antibody, leading to a
heterogeneous mixture that makes batch to batch con-
sistency hard to effectuate [21]. To overcome these prob-
lems associated with chemical conjugation of a cargo to
an Sn-specific mAb, we report here on the development
of a versatile recombinant antibody vector that allows easy
production and purification of defined genetic antibody
fusion constructs. The obtained vector will allow us to
generate functional antibody-cargo constructs to evaluate
Sn-targeting strategies in a porcine animal model.
Results
Development of a sialoadhesin-specific recombinant
antibody, rec41D3
To allow production and purification of genetic fusion
proteins of an Sn-specific mAb and other peptides/pro-
teins, a recombinant Sn-specific mAb was made. mAb
41D3 was previously described to selectively bind por-
cine Sn (pSn) and to be internalized into pSn-expressing
macrophages [10]. The variable domains of mAb 41D3
were sequenced and cloned in frame with a mouse IgG1
backbone. The IgG1 backbone was modified so that the
resulting plasmid p41D3 contains a C-terminal heavy
chain multiple cloning site, allowing removal of the
antibody’s heavy chain stop codon and insertion of pro-
tein encoding sequences (Figure 1A).
Transfection of HEK293T cells with plasmid p41D3
led to the secretion of a fully assembled IgG into the
culture medium of the same size as mAb 41D3, as
shown by Western blot analysis of cell culture superna-
tants using polyclonal antibodies specific for mouse im-
munoglobulins (Figure 1B). Recombinant antibodies
were purified from cell culture medium using protein G
chromatography and dialyzed to PBS. To assess the pur-
ity of rec41D3 after purification, protein samples were
Figure 1 Development, production and purification of a pSn-specific recombinant antibody, rec41D3. (A) Vector map of p41D3 (B) Non-
reducing Western blot analysis of hybridoma supernatant of mAb 41D3 compared to p41D3-transfected HEK293T cell supernatant using
polyclonal antibodies specific for mouse immunoglobulins (C) SDS-PAGE of protein G purified transfected cell supernatants to evaluate rec41D3
purity (D) Western blot analysis of purified rec41D3 using polyclonal antibodies specific for mouse immunoglobulins (E) Confocal microscopical
analysis of CHO cells and recombinant pSn expressing CHO cells (CHO-pSn) incubated with mAb 41D3, rec41D3 or isotype matched controls
mAb 13D12 and rec13D12 at 4°C for 1 hour. Cells were fixed and stained with FITC-labelled goat-anti-mouse IgG. Images represent a single
confocal z-section through the middle of the cell. Scale bar: 5μm (F) Kinetic profile of the pSn-41D3/pSn-rec41D3 interaction by Surface Plasmon
Resonance measurements. Immobilized pSn4D-Fc was flowed with rising concentrations of mAb 41D3 or rec41D3, after which injection was
halted and dissociation was monitored during 5 minutes. Sensorgrams were fitted to a bivalent model and an approximation of the equilibrium
dissociation constant was calculated. M, protein marker; mAb, mAb 41D3; rec, rec41D3; KD, equilibrium dissociation constant.
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conditions and Coomassie Blue staining was performed
(Figure 1C). The presence of a single band under non-
reducing conditions and the presence of two bands under
reducing conditions consistent with the sizes of the heavy
and light chains of an immunoglobulin showed that
protein G purification yields pure rec41D3. Western blot
analysis further confirmed that the bands present were
antibody light and heavy chain fragments (Figure 1D).
Immunofluorescence stainings of CHO cells express-
ing recombinant pSn (CHO-pSn, [22]) were performed
to assess the specificity of rec41D3 for pSn (Figure 1E).
With rec41D3, a bright surface staining, similar to that
of the native mAb 41D3, was seen only on CHO-pSn
cells, but not on wild type CHO cells, indicating specific
pSn recognition of rec41D3. Control stainings wereperformed with isotype matched irrelevant mAb 13D12
(gD of pseudorabies virus, [23]), and its recombinant
form rec13D12. Development, production and purifica-
tion of rec13D12 was identical to the procedures used
for rec41D3.
Since the final goal is to use rec41D3 as a targeting mol-
ecule for pSn, the affinity of rec41D3 for pSn is highly
important. Therefore, its affinity was determined using
Biacore. As a target, a soluble form of the pSn receptor,
consisting of the first 4 N-terminal immunoglobulin-like
domains of pSn fused to a human IgG Fc (pSn4D-Fc), was
coated on the affinity chips. Previously, mAb 41D3 was
shown to bind to this pSn4D-Fc [24]. As seen in Figure 1F,
both mAb 41D3 and rec41D3 bound with high affinity to
pSn4D-Fc, their equilibrium dissociation constants (KD)
were determined to be 35 and 250 pM respectively.
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macrophages
As our ultimate goal is to target pSn+ macrophages
in vivo, we studied the capacity of rec41D3 to bind pSn
and induce its internalization in in vitro cultivated primary
cells. Primary porcine alveolar macrophages (PAM) were
isolated and incubated with the recombinant antibody for
different time periods, after which they were fixed and
stained to visualize membrane-bound and internalized
antibodies. As for mAb 41D3, a clear membrane staining
was observed at time zero, while with increasing time,
pSn-positive endocytic vesicles became readily apparent
(Figure 2A). Also, at early time points, endocytic vesicles
of both antibodies were mainly present in the vicinity
of the plasma membrane, while with increasing time
endocytosed pSn was also localized closer to the peri-
nuclear region. Similar to mAb 41D3-induced pSn endo-
cytosis, rec41D3-induced pSn endocytosis is only partial,
as confocal microscopical analysis showed that a clear
membrane staining remains visible besides the endocytic
vesicles. As a control, PAM were incubated with irre-
levant, isotype matched mAb 13D12 and rec13D12. No
cell staining was observed with these antibodies (data not
shown).Figure 2 Analysis of rec41D3-induced pSn endocytosis and analysis o
lysosomal compartments. (A) Confocal microscopical analysis of mAb 41
Cells were incubated for the indicated time periods with either antibody a
mouse IgG. Images represent a single confocal z-section through the midd
41D3 or rec41D3 (green) and early endosomes (EEA1), late endosomes (CI-
Colocalization was calculated from confocal z-sections of 25 randomly sele
Data represent the means ± standard deviations. Representative images of
antibody are shown as overlays of the green and red signal with a yellowIn a previous study, we have shown that mAb 41D3
resides for prolonged times in early endosomes [10]. To
analyze the intracellular localization of internalized rec41D3
in comparison to mAb 41D3, double immunofluorescence
stainings were performed with EEA1, CI-M6P or Lamp1,
markers for early endosomes, late endosomes and lyso-
somes respectively. For both antibodies, the majority of
internalized antibody was localized to early endosomes
(around 60%, Figure 2B), while the remainder was localized
to late endosomes. Occasionally, a very limited number of
internalized antibodies were localized in a lysosomal com-
partment. These results show that rec41D3 follows an
endocytic pathway similar to mAb 41D3 and resides for
prolonged times in early/late endosomes.
rec41D3 targets its cargo V5 as well as eGFP towards pSn+
cells
The previous results clearly show that rec41D3 can be
used to target pSn-expressing macrophages. To be able
to evaluate targeting of a cargo, we aimed at generating
functional antibody fusion constructs in which a cargo is
coupled to the C-terminus of the heavy chain of the
antibody. During the generation of the rec41D3 plasmid,
a multiple cloning site was introduced at the C-terminusf colocalization between internalized antibody and endo/
D3- and rec41D3-induced pSn internalization in primary macrophages.
t 37°C, fixed, permeabilized and stained with FITC-labelled goat-anti-
le of the cell. (B) Analysis of colocalization between internalized mAb
M6P) or lysosomes (Lamp1) (red) in primary macrophages.
cted cells of 2 independent experiments at the indicated time points.
macrophages that were incubated for 60 minutes at 37°C with either
colour indicating colocalization. Scale bar: 5 μm.
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[25] was introduced between the C-terminal Fc part and
the cargo linked to rec41D3. This minimizes the risk that
unwanted interactions occur between rec41D3 and its
cargo, which could result in non-functional antibody and/
or cargo. Two fusion constructs were generated: one con-
struct containing a (G4S)2 linker fused to a V5 peptide tag
(rec41D3-V5), the other one containing a (G4S)4 linker
fused to eGFP (rec41D3-eGFP). The GS linker used to
generate rec41D3-eGFP is long, to ensure eGFP has the
opportunity to fold into a functional protein. HEK293T
cell transfection followed by protein G purification of the
supernatant clearly predominantly yields intact fusion
proteins as shown by SDS-PAGE (Figure 3A). Under non-
reducing conditions a single band was visible for both
fusion proteins, shifted in size in comparison to unmodi-
fied rec41D3. Under reducing conditions, it became clear
that the antibody’s light chains remained unchanged, whileFigure 3 Development of fusion constructs rec41D3-V5 and rec41D3-
cells. (A) SDS-PAGE analysis of protein G purified rec41D3-V5 and rec41D3
blot analysis of rec41D3-V5 and rec41D3-eGFP samples in comparison to u
polyclonal antibodies (GαM), a V5-specific mAb (αV5) and an eGFP-specific
rec41D3-eGFP internalization in CHO-pSn cells and primary macrophages (
1 hour at 37°C, fixed, permeabilized and stained with AF594-labelled goat-a
rabbit anti-GFP in combination with FITC-labelled goat-anti-rabbit polyclon
weak, the signal was enhanced to obtain good microscopical images. Imag
cell. M, protein marker; -, rec41D3; V5, rec41D3-V5; eGFP, rec41D3-eGFP. Scathe heavy chains were shifted in size, showing the acquisi-
tion of extra protein sequences. The presence of V5 or
eGFP at the heavy chains of rec41D3 was further con-
firmed by Western blot analysis (Figure 3B). These results
indicate that rec41D3-V5 contains a V5 peptide tag, while
rec41D3-eGFP contains an eGFP molecule.
To further analyze whether or not rec41D3-V5 and
rec41D3-eGFP carry their cargo towards pSn+ cells and
induce internalization into the cells, we incubated CHO-
pSn and PAM with the fusion constructs for one hour at
37°C. As shown in Figure 3C, both V5 and eGFP were
co-internalized together with rec41D3 in both cell types.
As a control, CHO-pSn and PAM were incubated with
irrelevant, isotype matched rec13D12 fusion constructs
rec13D12-V5 and rec13D12-eGFP. No staining was
observed with these constructs (data not shown). In
conclusion, these data show that rec41D3 allows the
targeting of peptides and/or proteins towards pSn+ cells.eGFP and analysis of their internalization into pSn-expressing
-eGFP constructs in comparison to unmodified rec41D3 (B) Western
nmodified rec41D3 using mouse immunoglobulin-specific goat
mAb (αGFP). (C) Confocal microscopical analysis of rec41D3-V5 and
PAM). Cells were incubated with rec41D3-V5 or rec41D3-eGFP for
nti-mouse IgG1 in addition to FITC-labelled mouse anti-V5 (IgG2a) or
al antibodies respectively. Since the rec41D3-eGFP fluorescence was
es represent a single confocal z-section through the middle of the
le bar: 5μm.
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Monoclonal antibodies and derivatives are currently the
fastest growing class of therapeutic molecules [26]. Their
inherent promise to minimize side effects by selectively
targeting specific target cells has fuelled their develop-
ment, leading to several FDA-approved antibody thera-
peutics so far and many more in the pipeline. Although
unmodified mAbs proved their worth, the conjugation of
effector molecules (like toxins, drugs, radionuclides,. . .) to
mAbs broadened their therapeutic potential, especially in
the domain of cancer therapeutics. Besides cancer, other
diseases could also benefit from antibody-directed thera-
pies, the only prerequisite being the identification of
a receptor exclusively expressed on those immune cells
involved in the induction of pathology. In this respect, sialic
acid-binding immunoglobulin-like lectins (siglecs) are com-
pelling candidates for therapy, as they display very restricted
expression patterns on subsets of immune cells and may
regulate immune cell functions. Furthermore, siglecs are
endocytic receptors allowing therapeutic agents conjugated
to amAb to be carried efficiently into the cell [27,28].
Sialoadhesin or Siglec-1 is expressed on cells of the
monocyte/macrophage lineage, notably on subsets of resi-
dent tissue macrophages and inflammatory monocytes/
macrophages [15,27]. A recent report describes the ex-
pression of Sn on human mature DCs treated with LPS
in vitro [29], suggesting that Sn may be present on mature
DCs during inflammation in vivo as well. Not only have
Sn+ monocytes/macrophages been described in several
diseases like inflammatory and autoimmune disorders as
well as viral infections, they also appear to play a role in
the initiation of an adaptive immune response as recently
shown by different independent research groups and
nicely reviewed by Martinez-Pomares and Gordon [1].
Together, this makes these Sn+ cells not only attractive
targets for cell-directed therapies, but also an appealing
target for vaccination. In our previous study, we developed
immunoconjugates by the chemical linkage of the model
antigen HSA or a toxin to the pSn-specific mAb 41D3
[10]. Although these immunoconjugates proved efficient
for boosting immune responses and killing pSn-
expressing cells respectively, the chemical linkage of the
cargo to a targeting antibody has many disadvantages.
First of all, chemical coupling procedures rely on the
presence and distribution of reactive groups, like e.g.
primary amines on lysine residues, that can be located
in or near the antigen-binding region, which upon
coupling might result in partial or complete loss of the
antibody’s affinity for the target antigen. Secondly, be-
cause of the large number of reactive groups present in
antibody molecules, a typical distribution can be observed
of zero to eight molecules per antibody [30,31], resulting
in high variation of the final conjugate. This variation is
unwanted, as it may lead to a heterogeneous mixture ofcomponents with distinct affinities, stabilities, pharmaco-
kinetics, efficacies, and safety profiles [21]. Moreover,
chemical coupling implies that both antibody and cargo to
be linked are independently produced and purified, which
represents a significant challenge, especially when the
cargo is also a biologic. To circumvent these problems, we
opted to generate a recombinant form of the pSn-specific
mAb 41D3. As shown in this study, this recombinant anti-
body displays a comparable affinity for pSn compared to
the native mAb. In addition, the recombinant mAb also
induces pSn endocytosis in primary macrophages, a fea-
ture important to allow functionality of antibody-cargo
constructs. As protein sequences are attached to the C-
terminus of the antibody’s heavy chain, they are less likely
to hinder antigen binding by the variable immunoglobulin
domains. In addition, each heavy chain will contain only
one cargo fused to the C-terminal end. This will result in
an antibody with 2 cargos in a defined position and a high
intra and inter batch consistency. Furthermore, we could
purify the antibody-cargo fusion proteins using standard
protein G chromatography, which represents a major ad-
vantage compared to chemical coupling in which purifica-
tion is needed for both cargo and antibody before, as well
as after chemical conjugation.
In this study we managed to make genetic fusion con-
structs of a peptide or a protein linked to our recombin-
ant mAb. Obviously, the recombinant antibody vector
does not allow to make genetic fusion constructs with
chemical compounds. For vaccination strategies how-
ever, this limitation is not expected to pose any pro-
blems, as most antigens used in vaccines are protein
based. One challenge however would be to ensure
correct folding of the antigen upon genetic fusion to the
antibody and to maintain this fold during purification
procedures. Similarly, immunotoxins can be made using
the Sn targeting vector. Although the production of
immunotoxins in eukaryotic cells has been limited due
to potential toxicity to the producing cells, several inde-
pendent research groups have reported on the successful
production of immunotoxins in mammalian cell lines,
including HEK293T [32-34]. In case a specific applica-
tion would require the chemical linkage to an antibody,
e.g. when vaccines are based on glyco-epitopes, a recom-
binant mAb has some major advantages. It allows
addition of specific amino acid modifications to the anti-
body, which will result in site-specific incorporation of
drug molecules through chemical linkage yielding batch
to batch consistency of antibody-drug conjugates. Exam-
ples of such already implemented modifications are the
THIOMABTM technology of Genentech Inc [35] or the
methodology of Axup et al. [21].
As our future plans include the use of the developed
recombinant antibody to target antigens towards pSn-
expressing macrophages in vivo, one might be concerned
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Poderoso et al. previously used mouse mAbs as surro-
gate antigens in pigs to evaluate the role of Sn in the
induction of humoral responses and noticed an en-
hanced anti-mouse antibody response in comparison
with a non-targeting isotype control mAb [11]. The in-
duction of anti-mouse antibodies was however low after
primary injection of the mAb, only after a booster
vaccination antibody titres rose significantly. Previously,
we have observed an enhanced anti-HSA antibody re-
sponse after a single dose vaccination of HSA coupled to
mAb 41D3 without adverse clinical effects [10]. There-
fore, in our future experiments, we will use a single dose of
rec41D3-antigen to evaluate the protective efficacy of anti-
gen targeting to pSn. If further experiments confirm the
applicability of this targeting technology, ‘porcinization’ of
the recombinant antibody will be examined to enable
prime-booster vaccination schedules.
Conclusions
A recombinant antibody that targets sialoadhesin was
developed. In addition, we constructed a vector that al-
lows the genetic linkage of a protein cargo in a defined
position at the C-terminus of both heavy chains of a
fully assembled antibody. This vector was shown to be
versatile, as both a peptide and a more complex, larger
protein could be fused. Furthermore, production and
purification of the antibody fusion constructs did not
require major optimization. In comparison to other Sn
targeting strategies (glycan-coated liposomes and cationic
hydrogels), the one-step production of the final carrier-
cargo product together with the high specificity and affi-
nity of the recombinant antibody may be considered an
advantage for drug development. Future research will
mainly focus on the development of functional antibody-




The experimental procedure for the collection of porcine
alveolar macrophages was authorized and supervised by
the Ethical and Animal Welfare Committee of the Fa-
culty of Veterinary Medicine of Ghent University.
Cell culture and monoclonal antibodies
PAM were isolated from 4- to 6-week-old conventional
Belgian Landrace pigs as described [36], and cultivated
in RPMI-1640 medium supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 1% non-essential
amino acids and 1 mM sodium pyruvate. HEK293T
were grown in DMEM medium supplemented with 10%
heat-inactivated FBS, 2 mM L-glutamine and 1 mM so-
dium pyruvate. CHO-K1 cells and CHO-K1 cells stablyexpressing recombinant pSn [22] were cultivated in F-
12 medium supplemented with 10% FBS and 1 mM so-
dium pyruvate. All culture media were supplemented
with a mixture of antibiotics and cell cultures were kept
in a humidified 5% CO2 atmosphere at 37°C.
MAb 41D3, directed against pSn [37,38], and isotype
matched (IgG1) control mAb 13D12, directed against
pseudorabies virus glycoprotein gD [23] were purified
from hybridoma supernatants using protein G sepharose
column chromatography (GE Healthcare), dialyzed to PBS
and stored at −70°C until use.Construction, production and purification of rec41D3,
rec13D12 and fusion constructs
The variable domains of mAb 41D3 were sequenced and
cloned into the pVITRO1-neo-mcs vector (Invivogen),
in frame with a mouse IgG1 backbone (Fusion Anti-
bodies Ltd). For the construction of rec13D12, total
RNA from 107 hybridoma cells was isolated (RNeasyW
mini kit, Qiagen) and cDNA was synthesized by RT-PCR
(SuperscriptW III First-Strand Synthesis System, Life
technologies). DNA sequences of mAb 13D12 VH and
VL were obtained based on the protocol described by
the Mouse Ig-Primer Set of NovagenW. Subsequently,
the variable domains of rec41D3 in pVITRO1-neo-mcs
were exchanged by the variable domains of mAb 13D12,
yielding a plasmid encoding rec13D12.
To construct both rec41D3- and rec13D12-V5, a
(G4S)2-V5 DNA sequence was introduced at the 3
0 end








both rec41D3- and rec13D12-eGFP, a (G4S)4 DNA se-
quence was introduced first at the 30 end of the heavy
chain sequence using forward primer 50-AAACGATC
GGGCGGGGGAGGCTCCGGGGGAGGCGGGTCTGG
AGGCGGGGGAAGTGGCGGGGGAGGCTCAGCGGC
CGCAAA-30 and reverse primer 50- TTTGCGGCCG
CTGAGCCTCCCCCGCCACTTCCCCCGCCTCCAGA
CCCGCCTCCCCCGGAGCCTCCCCCGCCCGATCGT
TT-30, followed by the eGFP sequence of pCeMM
CTAP(SG) (GenBank Accession number EF467048)
amplified by PCR using forward primer 50- AAAGC
GGCCGCAATGGTGAGCAAGGGCGAGGAG-30 and
reverse primer 50- AAAGGCCGGCCTTACTTGTACA
GCTCGTCCAT-30. Underlined sequences represent
enzyme restriction sites, sequences in italics represent
linker DNA sequences.
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constructs, HEK293T cells were transiently transfected
using calcium phosphate. Transfected cells were cultured
in DMEM supplemented with 10% IgG depleted, heat-
inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyru-
vate, and a mixture of antibiotics in a humidified 5% CO2
atmosphere at 37°C. Culture supernatant was collected
and IgG were purified from the supernatant using stand-
ard protein G sepharose chromatography following the
manufacturer’s instructions (GE Healthcare). Fractions of
the eluate containing the purified protein were pooled and
the buffer was exchanged to PBS by dialysis. Purified pro-
tein was stored at −70°C until use. Yields of recombinant
antibodies and fusion constructs from HEK293T super-
natant were ± 500 μg/l for rec41D3, rec13D12 and V5 fu-
sion constructs and ± 250 μg/l for eGFP fusion constructs.
SDS-PAGE, Coomassie blue staining and western blot
analysis of rec41D3 and fusion constructs
Samples of purified proteins were mixed with (non-) re-
ducing Laemmli buffer, boiled for 5 min and subjected
to SDS-PAGE (6% non-reducing gel, 10% reducing gel)
using a BioRad Mini Protean 3 system. For Coomassie
Blue staining, the SDS-PAGE gel was incubated succes-
sively in Ultra Pure water, Imperial™ protein staining
solution (Thermo Scientific) and Ultra Pure water as
destaining solution. Alternatively, for Western blot ana-
lysis, proteins were transferred from the SDS-PAGE gel
to a PVDF membrane (Membrane Hybond-P, GE
Healthcare) via Western blotting (BioRad Mini Trans
Blot). The membrane was blocked overnight in PBS +
0.1% Tween 20 + 5% skimmed milk. Detection of re-
combinant antibodies was performed by subsequent
incubation of the blot with peroxidase-labeled poly-
clonal goat anti-mouse antibodies (Dako), followed by
visualization using enhanced chemiluminiscence (ECL;
GE Healthcare). Alternatively, rec41D3-V5 protein
was detected using peroxidase-labeled anti-V5 anti-
bodies (Life technologies) and rec41D3-GFP protein
was detected using a recombinant rabbit monoclonal
GFP-specific antibody (ABfinity™, Life technologies) and
peroxidase-labeled polyclonal goat anti-rabbit anti-
bodies (Dako), followed by ECL visualization.
Surface plasmon resonance
The generation of a soluble Fc-tagged pSn has been de-
scribed before [24]. For Biacore experiments, a pSn4D-
Fc protein was used containing a single point mutation
in the first pSn immunoglobulin-like domain, since pro-
duction levels of this protein are significantly higher.
mAb 41D3 has been shown to equally bind to this pro-
tein [24]. After production and purification, pSn4D-Fc
was coupled to an activated CM5 chip to 300 responsive
units (RU). mAb 41D3 (300, 108, 39, 14 nM) or rec41D3(250, 90, 32, 12 nM) diluted in HBS-EP buffer was injected
(30 μl/min) for 2 min, followed by dissociation for 5 min.
Surface regeneration was performed with 10 mM NaOH
for 60 s followed by a recovery phase. The sensorgrams
were fitted to a bivalent model accounting for mass-
transfer effects.
Immunofluorescence stainings
To assess pSn specificity, CHO or CHO-pSn cells were
seeded on poly-L-lysine (Sigma) coated coverslips and in-
cubated with mAb 41D3, rec41D3 or isotype-matched
control antibodies mAb 13D12 and rec13D12 for 1 h at
4°C. Cells were then fixed with 4% (w/v) paraformalde-
hyde (Sigma) in PBS, permeabilized using 0.5% (w/v) sap-
onin (Sigma) in PBS and stained with FITC-labelled goat-
anti-mouse IgG to visualize antibodies bound to the cell.
To evaluate pSn endocytosis of rec41D3 in comparison
to mAb 41D3, PAM were incubated with 2 μg/200 μl
purified antibodies and cells were fixed with 4% parafor-
maldehyde at the indicated time points. Afterwards, cells
were permeabilized using 0.5% saponin and stained with
FITC-labelled goat-anti-mouse IgG to visualize antibodies
bound to and internalized in the cells. As a control, cells
were fixed (time 0) and incubated with the respective anti-
bodies afterwards. For double immunofluorescence stain-
ing with markers of the endosomal compartments, the
respective primary antibodies for each endosomal com-
partment followed by appropriate Texas Red-labelled
secondary antibodies was used for their visualization. The
primary antibodies used were an affinity purified goat
pAb (sc-6414; Santa Cruz Biotechnology), a rabbit pAb
(ab32815; Abcam) and a rabbit pAb (sc-5570; Santa Cruz
Biotechnology), for early endosome antigen 1 (EEA1),
cation-independent mannose-6-phosphate receptor (CI-
M6P) and lysosome-associated membrane protein 1
(Lamp1) respectively. Cell nuclei were visualized using
Hoechst 33342 (Life Technologies).
To evaluate pSn endocytosis of rec41D3 fusion con-
structs, CHO-pSn and PAM were incubated with 2 μg/
200 μl purified rec41D3-V5, rec41D3-GFP or their
respective isotype controls rec13D12-V5 and rec13D12-
eGFP for 1 h at 37°C. Cells were then fixed with 4%
paraformaldehyde, permeabilized using 0.5% saponin
and stained with AF594-labelled goat-anti-mouse IgG1
in addition to FITC-labelled mouse anti-V5 (IgG2a) or
rabbit anti-GFP in combination with FITC-labelled
goat-anti-rabbit polyclonal antibodies respectively. Cell
nuclei were visualized using Hoechst 33342 (Life
Technologies).
Confocal laser scanning microscopy
Z-section images of samples were acquired using a Leica
TCS SPE-II laser scanning spectral confocal system
(Leica Microsystems GmbH) linked to a Leica DM2500
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tion was done using the Leica LAS AF confocal software
package and analysis of colocalization was done using
CoLocalizer Pro [39]. For the colocalization analysis be-
tween Sn and the endosomal markers, the Sn-positive
plasma membrane was excluded from the analysis and
only internalized Sn was considered.
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